Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

Locally Advanced Cervical Cancer

Interventions

DRUG

Zimberelimab

240mg,d1,iv,Q21D

DRUG

Albumin-bound Paclitaxel

260mg/m2,d1,iv,Q21D

DRUG

Cisplatin

75mg/m2,d1,iv,Q21D

Trial Locations (1)

RECRUITING

Hongxi Zhao, Xi'an

All Listed Sponsors

lead

Tang-Du Hospital

OTHER